Although further studies, such as the relationship between the effect of Nrf2 activation and its threshold in each kidney disease model, are required, future clinical application of Keap1-Nrf2 PPI inhibitor to CKD is expected. The gene discussed is KEAP1; the disease is chronic kidney disease.